Post
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial – CNBC
- Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial CNBC
- Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly
- Lilly’s Experimental Diabetes Shot Yields Record Weight Loss in Study Bloomberg.com
- Lilly’s triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial Fierce Biotech
- Lilly’s next-gen obesity drug shows reduction in blood sugar levels in trial Yahoo Finance